Education
About Us
Working with TipRanks
Follow Us
Oncopeptides AB (SE:ONCO)
:ONCO
ONCO Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.10 - kr6.96
Previous CloseN/A
Volume80.98K
Average Volume (3M)9.05M
Market Cap
kr1.13B
Enterprise Valuekr323.41M
Total Cash (Recent Filing)kr107.22M
Total Debt (Recent Filing)kr118.39M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding211,263,900
10 Day Avg. Volume4,229,753
30 Day Avg. Volume9,049,732
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr5.00Price Target Upside-0.79% Downside
Rating ConsensusHold
Number of Analyst Covering0
Oncopeptides AB News
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.10 and its highest was kr6.96 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr1.13B.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Aug 21, 2025 which is 2 days ago.
How were Oncopeptides AB’s earnings last quarter?
Currently, no data Available
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 211,263,900 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
Company Description
Oncopeptides AB
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Xspray Pharma AB
―
Active Biotech AB
―
Cantargia AB
―
Ownership Overview
0.66% Insiders
―
Mutual Funds
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---